Clinical Trials Details

A011801 CompassHER2-RD (Breast)

The CompassHER2 Trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive Breast Cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DMI and placebo compared to T-DMI and Tucatinib

Objective

Key eligibility: HER2+ RD after pre-op chemo and HER2-directed treatment; any ER-T1-4, N0-3 at presentation; at least 6c of chemotherapy pre-op or pre- and post-op.

» Learn more about this trial

Clinical Trial Categories

  • Cancers and Other Neoplasms